A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod

Fox, Paul J.; Nathan, Mayura; Francis, Nicholas; Singh, Naveena; Weir, Justin; Dixon, Glen T.; Barton, Simon; Bower, Mark

doi:10.1097/qad.0b013e32833d466c

Cited by 111 publications

(84 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…La dysplasie sévère est traitable par électro destruction au bloc opératoire ou en consultation et par la pommade Imiquimod ® au prix de multiples procédures [9].…”

Section: Pourquoi Dépister ?unclassified

“…La présence d'une élytrocèle associée à la rectocèle va faire privilégier une voie haute par coelioscopie. En cas de rectocèle isolée, la voie d'abord sera basse, par voie périnéale ou vaginale (risque de dyspareunie dans 8 à 26 % des cas devant conduire à l'éviter chez la femme jeune et à ne pas faire de myorraphie trop serrée des releveurs) [8,9] ou par voie rectale (risque de récidive).…”

Section: Quel Traitement Chirurgical ?unclassified

See 1 more Smart Citation

Réunion de la Commission proctologie du CREGG-Monaco - 27 septembre 2013

Higuero¹

2014

Hegel

View full text Add to dashboard Cite

“…La dysplasie sévère est traitable par électro destruction au bloc opératoire ou en consultation et par la pommade Imiquimod ® au prix de multiples procédures [9].…”

Section: Pourquoi Dépister ?unclassified

Section: Quel Traitement Chirurgical ?unclassified

Réunion de la Commission proctologie du CREGG-Monaco - 27 septembre 2013

Higuero¹

2014

Hegel

View full text Add to dashboard Cite

“…The patients presenting anal warts that were identified during the anoscopy were treated with 90% trichloroacetic acid (TCA) and 5% imiquimod for 12 weeks [18].…”

Section: Methodsmentioning

confidence: 99%

High-Risk HPV DNA Test for Screening Anal Lesions in HIV-Positive and Negative Patients

Cruzand¹

2014

J AIDS Clin Res

View full text Add to dashboard Cite

The high incidence of anal dysplasia is related to many factors. The infections caused by HPV and HIV seem to be determinants of the following anal Pap smear changes: atypical squamous cells of undetermined significance (ASCUS), low-grade anal intraepithelial neoplasia (LAIN) and high-grade anal intraepithelial neoplasia (HAIN). Highrisk HPV infection is confirmed by the HPV DNA test, using hybrid capture technology. Screening for anal lesions should be complemented with the anal Pap smear protocol and high-resolution anoscopy. The aim of this study was to evaluate the influence of the high-risk HPV DNA test on screening for anal lesions. We evaluated 70 HIV-positive and negative patients who had previously had anal intercourse, at CRT/AIDS São Paulo from January 2013 to December 2013. All of the patients underwent the high-risk HPV DNA test, anal Pap smear protocol and highresolution anoscopy. The anal lesions were treated with 90% trichloroacetic acid (TCA) and 5% imiquimod for 12 weeks. The statistical analysis was performed using hypothesis tests on proportions and the significance level was set at less than 5%. 31 HIV-positive male patients, 19 HIV-negative male patients and 20 HIV-negative female patients were evaluated. 28 HIV-positive patients were positive for the high-risk HPV DNA test and 29 patients were positive for the high-risk HPV DNA test and had anal dysplasia. Our conclusion is that it was more common for HIVpositive patients to be infected with oncogenic HPV and the oncogenic HPV was more frequent in patients with anal dysplasia.

show abstract

“…Better data on treatment of AIN are available for the local immunomodulator imiquimod, including a prospective controlled trial [52]. Intra-anal imiquimod-containing suppositories could eradicate AIN in up to 74% and reduce HPV positivity after 12-16 weeks of treatment [53,54].…”

Section: Treatment Of Ainmentioning

confidence: 99%

HIV-Associated Anal Dysplasia and Anal Carcinoma

Oette¹,

Mosthaf²,

Sautter-Bihl³

et al. 2017

Oncol Res Treat

View full text Add to dashboard Cite

Anal carcinoma shows an increasing incidence in people living with human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) in whom it is also much more common compared to the HIV-negative population. Human papillomavirus infection is the etiological basis of malignant development in the anal epithelium. Therefore, adequate diagnosis and treatment of the precursor lesions (anal intraepithelial neoplasia) is of clinical importance. In cases with preserved immune function, anal cancer can be treated according to guidelines issued for HIV-negative patients. This review summarizes the current knowledge regarding anal malignancies in HIV-positive patients.

show abstract

A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod

Cited by 111 publications

References 10 publications

Réunion de la Commission proctologie du CREGG-Monaco - 27 septembre 2013

Réunion de la Commission proctologie du CREGG-Monaco - 27 septembre 2013

High-Risk HPV DNA Test for Screening Anal Lesions in HIV-Positive and Negative Patients

HIV-Associated Anal Dysplasia and Anal Carcinoma

Contact Info

Product

Resources

About